Melanie Cole: Welcome to a HN Med Talks, an informative resource for
physicians across various specialties as we delve into the latest medical
insights and best practices, ensuring you stay at the forefront of your field.
I'm Melanie Cole, and today we're highlighting advanced
treatments in melanoma.
Joining me is Dr.
Deanna Huffman.
She's a medical-oncologist with the A HN Cancer Institute.
Dr.
Huffman, thank you so much for joining us today.
Just start by telling us a little bit about melanoma,
the prevalence and incidents.
What are you seeing in the trends these days?
Dr. Deanna Huffman:
Yeah.
Thank you so much for having me to talk about melanoma today.
So.
Melanoma is becoming more prevalent as the years go on.
You know, you wouldn't think of it being so common here in Western
Pennsylvania, but I can tell you we're, pretty busy in the melanoma
sector over at West Penn Hospital.
as screening techniques are becoming more, evolved, we're actually detecting melanoma
sooner, which is great for treatment outcomes of patient's, but it also means
we are seeing more cases of melanoma.
Melanie Cole: That is interesting.
Now tell us a little bit about the melanoma and skin cancer
Center of Excellence at WPH.
Tell us about the multidisciplinary team that you have there And
what makes you so unique?
What are you offering there?
Dr. Deanna Huffman:
We have a wonderful comprehensive center over at West Penn, which is just amazing.
so we encourage you to refer any skin cancer patient's over there.
We have myself as a medical-oncologist.
We also consult with Dr.
Pavi, who's out of Wexford as a medical-oncologist, we have a team
of onco dermatologists led by Dr.
Mount.
We have surgical oncologists led by Dr.
Ton.
We have specialized dermatopathologist.
Radiation-oncologist, And we all get together.
We have a collaborative clinic over at West Penn where we help screen
patient's and come up with best treatment options as well as ongoing
clinical trials at West Penn Hospital.
Melanie Cole: So what's new, Dr.
Huffman?
What's exciting in screening and diagnosis?
You said it's a pretty busy clinic, so you know, as we always know,
early detection is paramount to those better outcomes, as you said before.
So what are we doing as far as screening and diagnosis for
at-risk and not at-risk people?
Dr. Deanna Huffman:
So I think the most exciting thing we have going on.
As far as screening, especially at West Penn is we have a machine called
the the Vectra 3D Body Imaging.
we're the only center in western Pennsylvania that has one.
And what it is, is it's basically a 3D camera that takes, a snapshot
of a patient's whole body and uses AI algorithms to track changes in
moles, which may be a little bit more, intuitive than maybe the naked eye
from a dermatologist following 'em.
You know, not only.
Is it maybe more advanced than the naked eye, but it's also more efficient, allows
us to screen patient's more quickly.
And so patient's can come in and get their Vectra scan however often it is
recommended by their dermatologist, whether that be once every six
months, once a year, without having to wait to meet with a provider.
'cause as we all know, wait times to get into dermatology can be quite long.
So that's something we're most excited about over at West Penn.
Melanie Cole: That's pretty cool.
So now that we've got screening and diagnoses, advancements speak about
treatment options for advanced melanoma, you can speak about non advanced melanoma.
You know, at first diagnosis.
Early stage, but then segue into advanced and what's going on today
as far as surgical medical treatment options for cancer that spread to
the lymph nodes and other organs.
Dr. Deanna Huffman:
So melanoma is a field where we are rapidly gaining new insights all the time.
the advent of immunotherapy And the treatment for melanoma has totally
revolutionized treatment in the last 10 years, and now we have.
Immunotherapies that are approved for early stage melanoma as well, whether
in the adjuvant or neoadjuvant setting, either before or after surgery, as well
as in advanced metastatic patient's.
So always recommend a referral as early as possible so we can assess patient's
for treatments that might improve, their chance of recurrence, reduce their risk
of recurrence, and improve their outcomes.
And then additionally for metastatic patient's for more advanced patient's.
Beyond immunotherapies.
We have lots of trials going on at West Penn.
And of course, all over the nation, but what we're most excited about
is something called TIL Therapy Tumor infiltrating Lymphocytes.
So it's actually gotten an FDA approval since 2024 for patient's
with relapsed metastatic melanoma.
So patient's who have already failed one line of therapy.
And that's something that we can offer at West Penn to our
patient's, just from a commercial standpoint, from an FDA approval.
But we also have ongoing clinical trials with TIL therapy working in how to improve
these types of therapies, how to reduce toxicities from these type of therapies.
So we're really excited about that.
We also have research going on in, oncolytic viral proteins, kind of vaccine
development against cancer as well.
Melanie Cole: That is exciting.
It's a pretty exciting time in your field.
And what about some of the treatments for refractory or recurrent disease?
What's going on in that realm?
Dr. Deanna Huffman:
So again, that's another area where Til Therapy would be
very useful, very exciting.
We also offer.
Clinical trials, immunotherapy based clinical trials until based
clinical trials, And then of course, BRAF directed therapy.
So we use genetic sequence like in most cancers nowadays, to look for
specific gene targets, namely one being BRAF, which can be positive and up
to two-thirds of melanoma patient's.
And we can use targeted therapies as well for advanced cases.
Melanie Cole: Yeah, til therapy is pretty exciting.
And do you have any clinical trials, Dr.
Hoffman going on at a HN that you wanna mention to other providers?
Dr. Deanna Huffman:
Sure.
So we actually have two clinical trials going on right now for TIL Therapy.
the first one is called.
Obsidian.
And so that's for patient's in kind of the typical setting, patient's
who have relapsed metastatic melanoma refractory disease who
have failed one line of therapy.
But the cool thing about this clinical trial, it's looking at ways to reduce
toxicity from til therapy and easier.
ways to, get the TILs out of the patient's in a safer, more effective way.
So that's a trial that most patient's would be eligible
for with refractory disease.
So we definitely encourage referral for your advanced patient's.
Another trial we have going on is called Iovance Melanoma, and that's
actually a first-line metastatic trial, which is really exciting.
So patient's with newly diagnosed, advanced or metastatic disease,
they've never had any treatment before.
and that's looking at the combination of immunotherapy with alongside TIL therapy.
So again, if you have any questions at all, we encourage you to reach
out to the A HN Skin Cancer website.
Send us a message, send us a referral on Epic, and we'd be happy to evaluate
your patient's for clinical trials.
Melanie Cole: Well, it seems like you have a lot more tools in your toolbox, and when
someone hears a diagnosis of melanoma.
Dr.
Hoffman, it can be life altering.
You know that it hasn't gotten great rap in the media.
And so speak a little bit about working with the patient's and
their families And the psychosocial aspect of this while they're trying
some of these available therapies.
Dr. Deanna Huffman:
Yeah, I think one of the things That is most.
Interesting about melanoma, is that it?
It is so heterogeneous, you know, it doesn't discriminate.
We can see patient's of all ages.
We see young, healthy patient's And we often see elderly patient's as well.
And the good thing about That is it opens us up to a lot more treatment
options when the patient's are a little more healthy to start It also
allows us for a higher chance of cure.
these patient's often go on to live very long lives, so it's really important
to consider early therapies And the toxicities that may come with therapies.
So it's really given us a chance to take a holistic approach to cancer care at
the Skin Cancer Center at West Penn.
Melanie Cole: Dr.
. Hoffman, as we get ready to wrap up.
You've mentioned early referral a few times.
I'd like you to describe a little bit about what that really means to
referring physicians, dermatologists, community physicians, And what makes
the A HN Cancer Institute at West Penn.
Really that center of excellence.
Dr. Deanna Huffman:
Yeah.
I think for us early referral means the first-time you notice an abnormal lesion
or even prior to that, when you have a patient who has a strong family history
of things like melanoma and other skin cancers, or maybe at high-risk because
of their history of sun exposure or other immunosuppressive medications.
We're always happy to see those patient's.
And the reason is because we have so many tools at West Penn.
we have excellent surgical oncologists who are up-to-date And the most appropriate.
ways to surgically resect melanomas because there are a couple
different methods out there.
And then also, we have multiple medical oncologists who can evaluate patient's
for need for therapy, even before surgery.
So that's what we mean by getting the patient in, the soonest possible is always
gonna be helpful for us in getting them the best, options for treatment, the best
options for surgery, And then help us get them plugged into appropriate screening,
all of which we can offer at West Penn.
Melanie Cole: Thank you so much Dr.
Huffman, for joining us today.
You've given us a lot to think about And so much great information.
Thank you so much again.
And to learn more or to refer your patient to Dr.
Huffman, please call 8 4 4 md.
Refer or visit find care.ahn.org.
Thank you so much for listening to this edition of A HN Med Talks
with the Allegheny Health Network.
I'm Melanie Cole.
Thanks so much for joining us today.